期刊
CLINICAL THERAPEUTICS
卷 42, 期 12, 页码 2280-2288出版社
ELSEVIER
DOI: 10.1016/j.clinthera.2020.10.002
关键词
bioavailability; food effect; hetrombopag; pharmacodynamics; pharmacokinetics
资金
- Jiangsu HengRui Medicine Co., Ltd.
- Major Specific Project of Sichuan Province of China [2020YFS0034]
- National Natural Science Foundation of China [81903722]
- Ministry of Science and Technology of China [2017ZX09304023]
Purpose: Hetrombopag, a novel, oral small molecule thrombopoietin receptor agonist, exhibits an obvious thrombocytopoietic effect with good safety. Hetrombopag is currently under clinical development for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). The objectives of this study were to assess the effect of high-fat and high-calorie food on the pharmacokinetic and pharmacodynamic (PK/PD) profiles of hetrombopag in healthy volunteers. Methods: An independent, single-dose, open-label, randomized-sequence, crossover trial was conducted. Healthy volunteers received hetrombopag 7.5-mg tablets in the fasted state or with a high-fat, high-calorie breakfast. The effects of the high-fat and high-calorie food on the PK/PD profiles of hetrombopag were evaluated by using a noncompartmental analysis and a semi-physiological model. Findings: Twelve Chinese healthy volunteers were enrolled. Mean plasma AUC(0-t) and C-max decreased by 98.7% and 95.0%, respectively, when hetrombopag was administered with high-fat and high-calorie food. The semi-physiological PK/PD model analysis showed that the absorption rate constant at the first absorption site was almost halved at the fed condition. The change in platelet counts in the fed condition was not sufficiently as sensitive as that in the fasted condition. (C) 2020 Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据